Lilly’s GLP‑1 Sales and PBM Coverage Fuel Record Quarter as Pipeline Logs Durable Wins

Overview

• Eli Lilly reported a blockbuster quarter with $19.8 billion in revenue driven largely by its tirzepatide drugs, and the company raised full‑year 2026 revenue guidance.
• The three largest U.S. pharmacy benefit managers agreed to cover Lilly’s full obesity portfolio, with CVS Caremark templates starting June 1 and broader commercial templates expected by October, and company pricing can let some patients pay as little as $25 per month.
• Early launch data show the oral GLP‑1 Foundayo had thousands of prescriptions in initial weeks and a single FDA adverse event report that regulators did not clearly link to the drug, with analysts noting routine data‑capture lags can undercount true demand.
• Lilly reported positive clinical advances that could change long‑term care: interim Phase 1b VERVE‑102 data showed large, durable PCSK9 and LDL‑C drops after one dose and a Phase 3 obesity candidate produced sustained, large weight loss in trials.
• A reported up‑to‑$1.55 billion deal to buy a nanoparticle vaccine developer has been covered by some outlets but remains unconfirmed by Lilly, and the company’s moves signal a push toward one‑time or durable therapies that could widen revenue sources and alter patient access and payer negotiations.